| Literature DB >> 34556052 |
Xueying Chen1, Jingfeng Wang1, Yixiu Liang1, Yangang Su2, Junbo Ge1.
Abstract
BACKGROUND: Leadless pacemaker has been acknowledged as a promising pacing strategy to prevent pocket and lead-related complications. Although rare, cardiac perforation remains a major safety concern for implantation of Micra transcatheter pacing system (TPS). CASEEntities:
Keywords: Case report; Coronary sinus; Leadless pacemaker; Pericardial effusion
Mesh:
Year: 2021 PMID: 34556052 PMCID: PMC8461975 DOI: 10.1186/s12872-021-02266-1
Source DB: PubMed Journal: BMC Cardiovasc Disord ISSN: 1471-2261 Impact factor: 2.298
Fig. 1Angiography showing Micra TPS placing into the coronary sinus: A At poster-anterior view; Pericardial effusion (arrow) at left anterior oblique view for the first attempt (B) and the second attempt (C)
Fig. 2The images showing the location of Micra leadless pacemaker: A. After deployment at right anterior oblique view; B. CT scan after implantation indicating the leadless pacemaker locating at the apex of right ventricular
Fig. 3The echocardiogram showing pericardial effusion (red arrow) during diastolic phase mainly distribution around the posterior wall of left ventricle
A time line from admission to 3 months after discharge
| Time line | Patient’s condition | Pacing parameters | Treatment | Medications |
|---|---|---|---|---|
| On admission | Normal | – | – | Aspirin (100 mg/day) and clopidogrel (75 mg/day) |
| During the procedure | Asymptomatic pericardial effusion with hemodynamically stable | Stable | – | – |
| At 2 h post-procedure | Pericardial tamponade | Stable | Pericardiocentesis and drainage of 270 ml bloody fluid | Stopped anti-platelet therapy for 5 days |
| On 6th day post-procedure | No pericardial effusion | Stable | Drainage tube removal | Aspirin (100 mg/day) and rivaroxaban (5 mg/day) |
| At 1-month follow-up | No pericardial effusion | Stable | – | Aspirin (100 mg/day), clopidogrel (75 mg/day) and rivaroxaban (5 mg/day) |
| At 3-month follow-up | No pericardial effusion, bleeding, thrombosis or thromboembolism | Stable | – | Aspirin (100 mg/day), clopidogrel (75 mg/day) and rivaroxaban (5 mg/day) |